BiotechTube

Interferon Beta-1A

Phase 1/2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent B Acute Lymphoblastic Leukemia

Conditions

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

Trial Timeline

Apr 1, 2025 → Oct 30, 2027

NCT ID
NCT05936229

About Interferon Beta-1A

Interferon Beta-1A is a phase 1/2 stage product being developed by Faron Pharmaceuticals for Recurrent B Acute Lymphoblastic Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05936229. Target conditions include Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia.

What happened to similar drugs?

4 of 20 similar drugs in Recurrent B Acute Lymphoblastic Leukemia were approved

Approved (4) Terminated (0) Active (16)
🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
✅Zopapogene imadenovec (Zopa)PrecigenApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
🔄Chemotherapy + Pembrolizumab + RamucirumabEli LillyPhase 3
🔄Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + RelugolixSumitomo PharmaPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05936229Phase 1/2Withdrawn

Competing Products

20 competing products in Recurrent B Acute Lymphoblastic Leukemia

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
KPL-914Kiniksa PharmaceuticalsPhase 2
29
KPL-387Kiniksa PharmaceuticalsPhase 2
36
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
34
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
Zopapogene imadenovec (Zopa)PrecigenApproved
44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
36
PLX3397Daiichi SankyoPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Drug Combination TherapySun PharmaceuticalPhase 2
42
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
Eribulin MesylateEisaiPre-clinical
26
Lenvatinib + EverolimusEisaiPhase 1/2
32
E7090EisaiPhase 2
42